Life-changing therapies

Innovative medicines pipeline
Macrocycle discovery platform
Collaborate with Polyphor

Latest news

• Polyphor to present at the H.C. Wainwright Global Investment Conference

• Polyphor announces financial results for the first half 2019 and realigns strategy

See all news

Meet us at

September 04, 2019	Publication Half Year Report 2019 Telecon 14:00h CET
September 05, 2019	UBS | Best of Switzerland Conference Dorint Airport-Hotel | Riethofstrasse 40 | CH-8152 Opfikon-Glattbrugg
September 06, 2019	KOL Meeting with Dr. Peter Kaufman, Co-Chair of the Balixafortide FORTRESS Trial Hotel The Benjamin | 125 East 50th Street | 10022 New York | 08:00h to 09:30h EDT | Webcast
September 09, 2019	Wainwright Investors Conference The Lotte Palace Hotel | 455 Madison Ave. | 10022 New York | USA
September 16, 2019	KOL Meeting with Dr. Javier Cortez, Co-Chair of the Balixafortide FORTRESS Trial Haus Zum Rueden | Limmatquai 42, Zürich | 12:15h to 13:45h CET | Webcast
September 18, 2019	Investora | Zürich Samsung Hall | Hoffnigstrasse 1 | CH-8600 Dübendorf | Presentation 15:25h – 16:10h

 

Event calendar

Innovative medicines pipeline

CXCR4 antagonist

Balixafortide (POL6326) – for novel immune-oncology agent for combination therapy

Fast Track Designation granted by FDA

Phase III

Antibiotics

Murepavadin (POL7080) – Pseudomonas infections

Preclinical

Discovery

Preclinical

Phase I

Phase II

Phase III

Approval

OMPTA platform –  targeting Gram-negative resistant pathogens

Lead preclinical compound: POL7306

 

Preclinical

Discovery

Preclinical

Phase I

Phase II

Phase III

Approval

Discovery

Preclinical

Phase I

Phase II

Phase III

Approval

Inhaled elastase inhibitor

POL6014 – Cystic Fibrosis

Outlicensed to Santhera Pharmaceuticals 14.02.2018

Phase I

Discovery

Preclinical

Phase I

Phase II

Phase III

Approval

Macrocycle discovery platform

New modalities to address challenging biological targets

Learn more